Evidence map›Paper›PMID 42417542›Full record

ReviewMolecular oncology2026

Astrocyte heterogeneity in brain metastases.

Carolina Hernández-Oliver, Neibla Priego, Manuel Valiente

Abstract readReview
In one paragraph

Review in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carolina Hernández-OliverBrain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0002-5613-7140
Neibla PriegoBrain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0002-2587-0104
Manuel ValienteBrain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0002-0647-7542

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastasis is increasingly understood as a disease of reciprocal adaptation between metastatic cells and the brain microenvironment. Among host cells, astrocytes have emerged as central regulators of metastatic colonization, survival, immune remodeling, and treatment resistance. Recent studies are re-defining astrocytes to explore the functional implications of their cellular heterogeneity. Evidence in brain metastasis indicates that astrocyte responses are heterogeneous across anatomical space, stage of colonization, and tumor type. This framework helps explaining how distinct astrocyte programs can coexist and why no single experimental platform captures their organization and complex biology. Moving toward spatially resolved, longitudinal, and functionally validated definitions of astrocyte states could clarify mechanisms and guide more precise therapeutic opportunities in brain metastasis. In this Viewpoint, we examine studies that have challenged the long-standing paradigm of astrocytes as a uniform entity, highlighting how recent technological advances reinforce previous findings and pave the way for identifying new therapeutic targets.

Indexed as

AstrocytesBrain NeoplasmsAnimalsHumansNeoplasm MetastasisTumor Microenvironmentastrocytesbrain metastasiscellular statesheterogeneitymicroenvironmenttherapeutic targets

Identifiers

PMID42417542
PMCPMC13399075

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.